P
Peter F. Billingsley
Researcher at University of Aberdeen
Publications - 133
Citations - 9164
Peter F. Billingsley is an academic researcher from University of Aberdeen. The author has contributed to research in topics: Malaria & PfSPZ vaccine. The author has an hindex of 46, co-authored 118 publications receiving 7810 citations. Previous affiliations of Peter F. Billingsley include International Centre of Insect Physiology and Ecology & Imperial College London.
Papers
More filters
Journal ArticleDOI
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Robert A. Seder,Lee-Jah Chang,Mary E. Enama,Kathryn L Zephir,Uzma N. Sarwar,Ingelise J. Gordon,La Sonji A. Holman,Eric R. James,Peter F. Billingsley,Anusha Gunasekera,Adam D. Richman,Sumana Chakravarty,Anita Manoj,Soundarapandian Velmurugan,Ming Lin Li,Adam Ruben,Tao Li,Abraham G. Eappen,Richard E. Stafford,Sarah H. Plummer,Cynthia S. Hendel,Laura Novik,Pamela Costner,Floreliz Mendoza,Jamie G. Saunders,Martha Nason,Jason H. Richardson,Jittawadee Murphy,Silas A. Davidson,Thomas L. Richie,Martha Sedegah,Awalludin Sutamihardja,Gary A. Fahle,Kirsten E. Lyke,Matthew B. Laurens,Matthew B. Laurens,Mario Roederer,Kavita Tewari,Judith E. Epstein,B. Kim Lee Sim,Julie E. Ledgerwood,Barney S. Graham,Stephen L. Hoffman +42 more
TL;DR: There is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.
Journal ArticleDOI
Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity
J. E. Epstein,Krishnansu S. Tewari,Kirsten E. Lyke,B. K. L. Sim,Peter F. Billingsley,Matthew B. Laurens,Matthew B. Laurens,Anusha Gunasekera,Sumana Chakravarty,Eric R. James,Martha Sedegah,Adam Richman,Soundarapandian Velmurugan,Sharina Reyes,Ming Lin Li,Kathryn Tucker,Adriana Ahumada,Adam Ruben,Tao Li,Richard E. Stafford,Abraham G. Eappen,Cindy Tamminga,Jason W. Bennett,Christian F. Ockenhouse,Jittawadee Murphy,Jack Komisar,N. Thomas,Mark Loyevsky,Ashley J. Birkett,Christopher V. Plowe,Christopher V. Plowe,Christian Loucq,Robert R. Edelman,Thomas L. Richie,Robert A. Seder,Stephen L. Hoffman +35 more
TL;DR: The results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Plasmodium falciparum malaria and suboptimally immunogenic and protective.
Book
Biology of the Insect Midgut
TL;DR: This work focuses on the structure and ultrastructure of the insect midgut, which is concerned with its role in digestion and transport, and its role as a target for control strategies in insects and other organisms.
Journal ArticleDOI
Sterile protection against human malaria by chemoattenuated PfSPZ vaccine
Benjamin Mordmüller,Güzin Surat,Heimo Lagler,Heimo Lagler,Sumana Chakravarty,Andrew S. Ishizuka,Albert Lalremruata,Markus Gmeiner,Joseph J. Campo,Meral Esen,Adam Ruben,Jana Held,Carlos Lamsfus Calle,Juliana Boex Mengue,Tamirat Gebru,Javier Ibáñez,Mihály Sulyok,Eric R. James,Peter F. Billingsley,Natasha Kc,Anita Manoj,Tooba Murshedkar,Anusha Gunasekera,Abraham G. Eappen,Tao Li,Richard E. Stafford,Minglin Li,Phil Felgner,Robert A. Seder,Thomas L. Richie,B. Kim Lee Sim,Stephen L. Hoffman,Peter G. Kremsner +32 more
TL;DR: PfSPZ-CVac is a highly efficacious vaccine candidate that could be used for combination mass drug administration and a mass vaccination program approach to eliminate malaria from geographically defined areas when able to optimize the immunization regimen.
Journal ArticleDOI
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.
Stephen L. Hoffman,Peter F. Billingsley,Eric R. James,Adam Richman,Mark Loyevsky,Tao Li,Sumana Chakravarty,Anusha Gunasekera,Rana Chattopadhyay,Minglin Li,Richard E. Stafford,Adriana Ahumada,Judith E. Epstein,Martha Sedegah,Sharina Reyes,Thomas L. Richie,Kirsten E. Lyke,Robert R. Edelman,Matthew B. Laurens,Christopher V. Plowe,B. Kim Lee Sim +20 more
TL;DR: Efforts are now focused on how best to achieve submission of a successful Biologics License Application and introduce the vaccine to the primary target population of African children in the shortest possible period of time.